Do you have any concerns surrounding compounded medication?

Two FDA-conducted surveys found that

of sampled compounded products failed one or more standard quality tests performed, including potency studies15

Help Eliminate the Variability of Compounding, Crushing, and Splitting9-11,15

Katerzia (amlodipine)
Oral suspension2 		Qbrelis (lisinopril)
Oral solution3 		Extemporaneously Compounded Suspension 15-19
Shake-and-Pour Convenience Once Compounded
Consistent Dosing
Payer Coverage Limited
FDA Approved
droplet

Avoid compounding and the potential for medication errors15,20

droplet

FDA-approved drugs ensure reliable concentration and consistency from fill to fill and pharmacy to pharmacy21

References:

1. Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children. Pediatrics. 2017;140(3):e20171904. 2. Katerzia [package insert]. Wilmington, MA: Azurity Pharmaceuticals Inc; 2020. 3. Qbrelis [package insert]. Wilmington, MA: Azurity Pharmaceuticals Inc; 2020. 4. Drugs@FDA: FDA-Approved Drugs. Search term: lisinopril. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed January 19, 2023. 5. Gutierrez-Colina AM, Smith AW, Mara CA, Modi AC. Adherence barriers in pediatric epilepsy: from toddlers to young adults. Epilepsy Behav. 2018;80:229-234. 6. Bhosle M, Benner JS, DeKoven M, Shelton J. Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations. Patient Prefer Adherence. 2009;3:161-171. 7. Chappell F. Medication adherence in children remains a challenge. Prescriber. 2015;26(12):31-34. 8. Zajicek A, Fossler MJ, Barrett JS, et al. A report from the Pediatric Formulations Task Force: perspectives on the state of child-friendly dosage forms. AAPS J. 2013;15(4):1072-1081. 9. Bachynsky J, Wiens C, Melnychuk K. The practice of splitting tablets: cost and therapeutic aspects. Pharmacoeconomics. 2002;20(5):339-346. 10. Gill D, Spain M, Edlund BJ. Crushing or splitting medications: unrecognized hazards. J Gerontol Nurs. 2012;38(1):8-12. 11. US Food and Drug Administration. Guidance for Industry. Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation. March 2013. 12. US Department of Health and Human Services. National Institutes of Health. Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics. https://www.nichd.nih.gov/sites/default/files/inline-files/2020PriorityListFeb20.pdf. Accessed February 13, 2023. 13. McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: a systematic review. Pediatrics. 2013;132(4):730-740. 14. Matsui D. Current issues in pediatric medication adherence. Pediatr Drugs. 2007;9(5):283-288. 15. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. 16. Allen LV Jr. Amlodipine 1 mg/mL oral liquid. US Pharm. 2014;39(2):55-56. 17. Lisinopril 1-mg/mL oral liquid. Int J Pharm Compound. 2006;10(4):302. 18. US Government Accountability Office. Compounded Drugs: Payment Practices Vary Across Public Programs and Private Insurers, and Medicare Part B Policy Should be Clarified. Report GAO-15-85. October 2014. https://www.gao.gov/products/gao-15-85. Accessed November 2, 2022. 19. US Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. January 2018. 20. Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021;17(2):197-217. 21. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72(16):2043-2050.